Introduction
Acid-base and electrolyte homeostasis is vital for proper functioning of numerous metabolic processes and organ functions in the human body. Kidneys play a critical role in the maintenance and regulation of this homeostasis. Kidney diseases and dysfunction (chronic kidney disease, CKD) compromise the regulatory functions, resulting in alterations in electrolyte and acid-base balances that can be life-threatening. We discuss the renal regulation of electrolyte and acid-base balance and several common disorders incorporating the most relevant advances in the field and with a focus on pathophysiology, clinical features, diagnosis and management in patients with and without CKD.
volatile acids are buffered in the body to prevent acute systemic pH perturbations. HCO 3 -/H 2 CO 3 is the major buffer system which neutralizes nonvolatile acids at the cost of HCO 3 - . Additionally, circulating phosphate, plasma and intracellular proteins, and bone all contribute to the buffering process. Kidneys are responsible for reclamation of all HCO 3 -filtered through glomeruli and generation of new HCO 3 -to replenish and re-balance the acid-base system. Kidneys also regulate phosphate balance and contribute to bone health through multiple mechanisms.
Renal Regulation of Acid-Base Balance
Under physiological conditions, renal net acid excretion (RNAE) is equal to net endogenous acid production. Such a balance is achieved via (1) reclamation of filtered HCO 3 -(approximately 4,500 mEq daily), and (2) urinary buffering, which includes (a) tubular regulation of titratable acids (TAs) and (b) generation and excretion of ammonia/ammonium (NH 3 /NH 4 + ). Approximately 80% of the filtered bicarbonate is reclaimed back into the circulation by the proximal tubule. The thick ascending limb of Henle (TALH) and distal convoluted tubule (DCT) reclaim an additional 16%, while the remaining 4% is reclaimed by the collecting ducts.
In the collecting ducts, intercalated cells are responsible for proton (H + ) and bicarbonate transport. Acid-secreting (type A) α-intercalated cells contain vacuolar H + -ATPase, located in the apical membrane. Bicarbonate exits the cells across the basolateral membrane via Cl --HCO 3 -antiporter (AE-1). Base-secreting (type B) β-intercalated cells are less abundant and have vacuolar H + -ATPase distributed in the basolateral membrane and a Cl --HCO 3 -antiporter (pendrin) in the apical membrane. Additional non-A, non-B interacted cells express both pendrin and H + -ATPase in the apical membrane [2] [3] [4] . There is compelling evidence for the existence of phenotypic plasticity amongst intercalated cells [5] . Moreover, β-and non-A, non-B intercalated cells are capable of transporting NaCl through pendrin and Na-dependent Cl --HCO 3 -exchanger, a NaCl absorptive pathway implicated in the genesis of salt-sensitive hypertension [4, [6] [7] [8] .
HPO 4 2-is the major urinary TA. HPO 4 2-is capable of incorporating H + , forming H 2 PO 4 -containing salt and excreted in the urine. For every H + incorporated and excreted, a HCO 3 -is gained. Other minor buffers are citrate, creatinine, and uric acid. TA excretion is responsible for approximately one-third of RNAE and is a low-capacity system, limited by dietary phosphate intake and the amount of filtered phosphate (HPO 4 2-). Parathyroid hormone and fibroblast growth factor 23 decrease renal proximal tubular phosphate reabsorption and thus can increase H + excretion. Approximately two-thirds of RNAE take place via renal generation and excretion of NH 4 + . Renal ammoniagenesis and excretion is a high-capacity system; it can increase many fold in response to increased acid-load, from a baseline of ∼ 30-40 to >250 mEq/day [9] . Ammoniagenesis occurs primarily in the proximal tubules, predominantly from glutamine metabolism. For 
Metabolic Acidosis and Serum Anion Gap
Metabolic acidosis can be broadly classified into (1) elevated anion gap (AG) acidosis and (2) normal AG acidosis. Symptoms of metabolic acidosis are summarized in In healthy adults, AG ranges from 8 to 12 mEq/L. AG should be corrected for alterations of serum albumin. For every 1 g/dL drop in serum albumin, expected AG should accordingly drop by 2.5 mEq/L (i.e., if albumin drops from 4.5 to 3.5 g/dL, expected AG should drop to 7.5 from 10 mEq/L). Other factors that may lower AG are the presence of cationic monoclonal gammopathy, polyclonal gammopathy, hypercalcemia, lithium and bromide, or iodide intoxication. Factors that could raise calculated AG, mostly by a small degree (<3 mEq/L), include hemoconcentration, metabolic alkalosis, severe hyperphosphatemia and elevated anionic paraproteins. 140 pancreatic or intestinal fistula, and ureteroileostomy, while renal loss of HCO 3 -or defect in H + excretion occurs in renal tubular acidosis (RTA). Type IV RTA is the most common form of RTA. Table 2 summarizes the characteristics of RTAs and their management. Another distinct entity, linked to the distal RTA, is incomplete distal RTA. Affected individuals develop hypocitraturia, nephrocalcinosis, and nephrolithiasis (calcium phosphate stones typically), but show a normal baseline acid-base status. They are typically unable to acidify urine in response to acid loading (typically oral NH 4 Cl). The underlying mechanism of this entity is unclear. Incomplete RTA is relatively common in patients with Sjögren syndrome, up to 25% in one study [15] . It is treated with potassium citrate.
Acidosis in CKD
The prevalence of metabolic acidosis increases with progression of CKD. In a cross-sectional analysis of the baseline data from the Chronic Renal Insufficiency Cohort (CRIC) study involving 3,900 patients in CKD stages 2-4, the prevalence of metabolic acidosis (serum HCO3 -<22 mEq/L) was 7% for CKD stage 2, 13% for CKD stage 3 and 33% for CKD 4 with an overall acidosis occurrence of 17.3% [16] . Normal AG acidosis is predominant in early stages of CKD; AG acidosis occurs in late stages (GFR <30 mL/min/1.73 m 2 ) due to retention of anions such as sulfate, phosphate, and urate. It should be noted that net endogenous acid production is relatively unchanged in CKD [17] . Intrarenal ammonia and acid retention, consequences of acidosis, can cause complement activation and chronic tubule-interstitial inflammation [18] and increased generation of endothelin-1, angiotensin II and aldosterone production [19] , potentially promoting CKD progression. Indeed, metabolic acidosis in CKD is associated with more rapid progression of CKD [17] and increased mortality [20] . In addition to the symptoms summarized in Table 3 (left column), acidosis in CKD is associated with the development of sarcopenia, bone demineralization, impaired function of growth hormone and insulin, and growth retardation in children.
Correcting metabolic acidosis with alkali administration [21] [22] [23] or dietary intake of alkali precursors [21, 24] slows CKD progression and improves nutritional status. KDIGO 2012 guidelines recommend correction of metabolic acidosis [25] . Oral NaHCO 3 is a commonly used alkali and may be initiated at a dosage of 650 mg (7.7 mEq of bicarbonate) 2-3 times daily. Dosage should be adjusted to keep serum HCO 3 -in the range of 22-26 mEq/L. The treatment is well tolerated and has not been shown to cause or worsen fluid retention and hypertension [26] . The most common adverse effects are bloating and abdominal fullness. Sodium citrate is an alternative agent but should be avoided in patients on aluminum-based phosphate binders due to the risk of aluminum intoxication.
Metabolic Alkalosis
Metabolic alkalosis can result from a net loss of acid or a net gain of bicarbonate (generation phase). The alkalosis is then perpetuated by hypokalemia, chloride depletion, hypovolemia or excessive mineralocorticoid stimulation. These conditions prevent the kidney from unloading the accumulated HCO 3 -(maintenance phase). Clinical manifestations are summarized in Table 3 (right panel). The major causes, pathophysiology, diagnostic features, and therapy in the general population are summarized in Table 4 .
Although less common than metabolic acidosis, metabolic alkalosis can occur in patients with CKD. CKD patients are commonly on diuretics as well as calcium carbonate or citrate which can cause hypokalemia and alkalosis. Diagnosis is based on elevations of serum HCO 3 -and pH (>7.45). Measurement of urine Cl -may not be helpful as renal Cl -regulation is likely impaired in CKD. Electrolyte disorders are common in CKD. Hyperkalemia is among the most common electrolyte disorders. Dysnatremia occurs more often in CKD due to compromised renal water regulation. The prevalence of dysmagnesemia in the CKD population is unclear but is likely underdiagnosed.
Potassium Regulation and Dyskalemia
is the most abundant intracellular cation, with >98% of total body K + (3,500 mEq) being intracellular and <2% (70 mEq) extracellular. The steep intracellular and extracellular K + gradient is the major determinant of the plasma membrane potential. K + also participates in the regulation of cell volume, pH and multiple cellular functions. In excitable tissues, such as heart, nerves, and skeletal muscle, K + is critical for the dynamic action potentials and electrical excitability. In a steady state, kidneys excrete approximately 95% of dietary K + , and the remainder is excreted through the gastrointestinal system. [27] and intestinal K + exposure [28] , independent of aldosterone and serum K + concentrations.
Renal Potassium Regulation
Potassium is freely filtered through glomeruli.
Hyperkalemia
Hyperkalemia is the most common electrolyte disorder in patients with CKD. Its prevalence increases as CKD progresses. In a retrospective study ( n = 240,000), CKD patients were more prone to hyperkalemic events (K + ≥ 5.5 mEq/L) than patients without CKD, with odds ratios of 2.2 for CKD stage 3, 5.9 for CKD stage 4, and 11 for CKD stage 5 [29] . Decreased glomerular filtration and ability of tubular K + secretion, often in combination with a diet generous in K + , are the major cause of hyperkalemia. Other causes of hyperkalemia pertinent to CKD patients are (1) medications that further reduce the already limited capacity of distal nephron K + excretion such as renin angiotensin aldosterone system inhibitors, K + -sparing diuretics and calcineurin inhibitors, (2) transcellular K + shift due to insulin deficiency, mineral metabolic acidosis, and tissue breakdown (hemolysis, rhabdomyolysis, tumor lysis syndrome), and (3) hyporeninemic hypoaldosteronism (type IV) RTA.
Hyperkalemia is defined as serum K + concentration >5.3 mEq/L and is often arbitrarily classified as mild (5.4 to <6 mEq/L), moderate (6 to <7 mEq/L), and severe ( ≥ 7 mEq/L) [30] . Symptoms and signs of hyperkalemia vary widely from nonspecific muscle weakness to paresthesia, muscle paralysis, cardiac arrhythmias, and cardiac arrest. Electrocardiogram may show arrhythmias, peaked T waves, prolonged PR interval, loss of P waves, widening of QRS complex and sine waves. It is important to note that ECG changes are not sensitive in detecting hyperkalemia. CKD patients can develop life-threatening hyperkalemia without appreciable EKG changes [31] .
Treatment for hyperkalemia should be multipronged. Dietary modification with initiation of a low K + diet (<75 mEq/day) is an important part of intervention. Medication regimen must be reviewed to minimize the exposure of drugs that may induce hyperkalemia. Loop and thiazide diuretics can be used to promote kaliuresis. Patiromer is a newer K + -lowering oral agent and can be tried when appropriate. Patiromer is a nonabsorbable, sorbitol containing Ca 2+ -K + exchange polymer that selectively binds K + mainly in the colon. Its onset of action is 7 h. Placebo-controlled clinical trials [32, 33] have demonstrated its efficacy and safety. It is FDA approved for treatment of chronic hyperkalemia in non-dialysis CKD patients in a nonacute setting. Patiromer comes as a powder (in 3 strengths of 8.4, 16.2, and 25.2 g) with a recommended starting dose of 8.4 g daily. Its dosage may be titrated up in increments of 8.4 g weekly to a maximum daily dose of 25.2 g. Its intake should be spaced at least 3 h apart from other medications due to a potential risk of drug-drug interaction. The most common known side effects are constipation and mild hypomagnesemia. Clinical symptoms and signs of hypokalemia depend on the rate of onset and severity. These include muscle weakness, cramps, muscle paralysis and respiratory failure, cardiac arrhythmias, paralytic ileus and rhabdomyolysis. Cardiac arrhythmias could include sinus bradycardia, A-V block, paroxysmal atrial or junctional tachycardia, ventricular tachycardia and fibrillation. EKG changes include loss of T wave, emergence of U wave, prolonged QTc and torsade's pointes. Hypokalemia increases renal proximal tubular ammoniagenesis and is associated with metabolic alkalosis. Prolonged hypokalemia is associated with renal cyst formation, parenchymal fibrosis, and CKD progression. In a study of patients ( n = 2,500) with CKD stages 1-4 (mean eGFR of 40.6 mL/min/1.73m 2) , those with hypokalemia (serum K + <3.5 mEq/L) had a significantly higher risk of developing ESRD than the risk in patients with serum K + of 4. 143 cell volume and function. Serum [Na + ] is tightly regulated by arginine vasopressin (AVP) and thirst in a narrow range of 135-145 mEq/L. AVP is produced in the supraoptic and paraventricular nuclei of the hypothalamus and released from the posterior pituitary in response to increased serum osmolality (sensed by osmoreceptors in the hypothalamus) and reduced intravascular volume (sensed by baroreceptors in the carotids and aortic arch). In the kidneys, AVP binds to V2 receptors in the basolateral membrane of collecting ducts, activates adenylyl cyclase-mediated cAMP production and PKA signaling, leading to increased production and phosphorylation/ apical membrane insertion of aquaporin 2 channels. This, in turn, leads to free water absorption in the presence of tubulomedullary osmotic gradient.
In a retrospective study involving a cohort of veterans ( n = 655,000) with non-dialysis-dependent CKD, Kovesdy et al. [35] found a U-shaped association between serum [Na + ] and mortality with both hypernatremia (Na + >145 mEq/L) and hyponatremia (Na + <136 mEq/L) associated with increased mortality. Hyponatremia Hyponatremia, defined as the serum [Na + ] <135 mEq/L, is the most common electrolyte disorder in both the community-dwelling population [36] and in hospitalized patients [37] with occurrence rates of 7.7-15 and 44%, respectively [38] . Patients with CKD are at higher risk of hyponatremia than the general population due to diminished GFR and tubular regulation. In the same study noted above, veterans with CKD (mean eGFR of 52 mL/min/1.73 m 2 ) were followed for a median period of 5.5 years, and 26% of the subjects developed at least 1 episode of hyponatremia [35] .
Clinical signs and symptoms of hyponatremia are relatively nonspecific and dependent on the severity and rate of hyponatremia onset. Patients with mild-to-moderate hyponatremia may be asymptomatic or present with malaise, nausea, lethargy and fatigue. The more overt neurological symptoms often manifest when hyponatremia is severe (<120 mEq/L) and has developed rapidly. Patients can present with headache, slowing of mentation, confusion, ataxia, seizures, and coma. Measurement of serum osmolality (normal serum osmolality = 280-290 mosm/kg) is necessary to rule out pseudohyponatremia, isotonic hyponatremia in the setting of hyperlipidemia and paraproteinemias, and hyperosmolar (>290 mosm/kg) hyponatremia in the setting of hyperglycemia or mannitol administration. Low serum osmolality (<280 mosm/kg) along with hyponatremia indicates true hypotonic hyponatremia. After confirming the presence of hypotonic hyponatremia, the patient's volume status should be determined to guide treatment decisions. Volume replacement with isotonic fluids is the treatment of choice in patients with volume depletion. Restoration of volume will turn off the stimulus for vasopressin release, leading to renal water excretion and correction of hyponatremia. Causes, clinical features, and treatment for euvolemic hyponatremia are summarized in Table 5 . Hypervolemic hyponatremia due to liver or heart failure should be treated with loop diuretics combined with free water restriction ( ≤ 1L/day). Vasopressin V 2 receptor blockers (vaptans) are not used routinely due to prohibitive cost and concerns of hepatotoxicity. The FDA has approved the use of tolvaptan, a selective V 2 receptor blocker, for less than 30 days for hyponatremia due to congestive heart failure but not for patients with cirrhosis. Several clinical trials have failed to show a reduction in long-term mortality and morbidity in heart failure patients treated with V2 receptor blocker despite increasing serum [Na + ] [39, 40] . Similarly, in a recently published TACTICS-HF study involving patients hospitalized for acute heart failure ( n = 257), randomization to 3 days of daily tolvaptan compared to placebo failed to show any difference in length of hospital stay, 30-day mortality, and 30-day re-hospitalization rates [41] . Similar results were found in the SECRET of CHF trial [42] . Patients with late-stage CKD often develop euvolemic or hypervolemic hyponatremia due to limited kidney function. Management involves free water restriction, use of loop diuretics and, if necessary, dialysis.
Regardless of the etiology, the rate of serum [Na + ] correction depends on 2 key factors: (1) whether the patient is symptomatic, and (2) the rate of hyponatremia onset (<48 h or ≥ 48 h). For symptomatic hyponatremia, 3% saline should be administered intravenously with the goal of raising serum ] >145 mEq/L) is relatively common with a reported incidence of 1-3.4% in hos-pitalized patients [36, 43] . In CKD, as cited above [35] , there is a reported 2% ( n = 13,289) prevalence of hypernatremia and 7% ( n = 45,666) occurrence of at least 1 episode of hypernatremia in non-dialysis CKD veterans with 5.5 years follow-up.
Hypernatremia signifies total body water deficiency relative to total body sodium. It can result from either (1) loss of water or hypotonic fluid (loss of water > loss of Na + ) or (2) gain of Na + (and K + ), such as incidental hypertonic fluid ingestion or infusion. Diabetes insipidus, chronic hypokalemia, hypercalcemia, hyperglycemia, and medications such as loop and osmotic diuretics, lithium, and vasopressin V 2 receptor blockers can cause hypernatremia due to renal hypotonic fluid loss. Nonrenal causes of hypernatremia include osmotic diarrhea, vomiting, excessive sweating, and burns. Sustained hypernatremia typically occurs when thirst mechanism is impaired (thirst stimulates AVP secretion leading to renal water preservation) and or there is lack of access to water. Hence, intubated patients, patients with altered mental status or under sedation, elderly nursing home residents, and infants are more susceptible to hypernatremia.
Clinical symptoms and signs of hypernatremia are nonspecific and vary from asymptomatic to comatose depending on the severity and rate of onset of hypernatremia. Common manifestations include intense thirst (if thirst mechanism is intact), fatigue, and lethargy, muscle weakness, slowing of mentation, confusion, and coma.
Hypernatremia is a hypertonic state. Thus, measurement of serum osmolality is, in general, unnecessary. Measurement of urine osmolality is useful in differentiating renal water loss such as diabetes insipidus (inappropriately dilute urine) from extrarenal water loss (concentrated urine). In patients on diuretics, urine osmolality may vary depending on the timing of diuretic intake. Patients with severe hyperglycemia can be in a hyperosmolar state, but their serum [Na + ] may be falsely normal or even reduced. Typically, serum [Na + ] is reduced by ∼ 1.6 mEq/L for each 100 mg/dL elevation of glucose above normal range.
Management of hypernatremia should focus on (1) correction of the underlying cause and (2) gradual, not exceeding 8-10 mEq/L in the first 24 h to prevent cerebral edema [44] . More rapid serum Na + correction (up to 1 mEq/L per hour) may be appropriate if onset of hypernatremia is acute (<48 h).
Total body free water deficit in hypernatremia can be estimated with the following formula:
Free water deficit = total body water × [(serum [Na + ]/140) -1] Where total body water = body weight × (0.6 for men; 0.5 for women)
The calculation provides an initial estimate of total body water deficit. The rate and amount of daily water replacement should be based not on the calculated water deficit, but on the repeated measurements of serum [Na + ] to prevent under-or overcorrection. through ROMK channels, which are, in turn, powered by the basolateral Na + /K + -ATPase. In the DCT, Mg 2+ reabsorption is transcellular via TRPM6, driven by the transapical membrane potential. As this is the last part of the renal tubular Mg 2+ absorption and there is a steep transepithelial Mg 2+ concentration gradient, the transapical membrane potential is tightly regulated through multitudes of channels and transporter proteins, detailed in a recent review [45] . Both hypermagnesemia (>2.3 mg/dL) and hypomagnesemia (<1.7 mg/dL) are relatively common with reported prevalence of 31 and 20%, respectively, in hospitalized patients [46] . Both hypo-and hypermagnesemia adversely impact patient outcomes, including increased mortality and longer duration of hospital stay. Causes, pathophysiology, and special features of different conditions causing hypomagnesemia and hypermagnesemia are summarized in Table 6 .
Magnesium Regulation and Dysmagnesemia
Symptoms of dysmagnesemia vary significantly. Mild hypo-or hypermagnesemia may be asymptomatic. Severe and chronic hypomagnesemia can present with muscle weakness, paresthesia, tetany, and seizures. It can potentiate cardiac arrhythmias. Severe hypermagnesemia can cause loss of deep tendon reflexes and paralysis.
In early stages of CKD, decreased filtration of Mg 2+ is balanced by reduced renal tubular reabsorption; hence, dysmagnesemia is uncommon. In advanced CKD, hypermagnesemia can be triggered by Mg 2+ -rich diet and Mg 2+ -containing medications. Hypomagnesemia in CKD patients can occur due to inadequate intake, poor intestinal absorption (due to malabsorption syndromes or use of proton pump inhibitors) and renal or extrarenal loss such as chronic diarrhea.
Treatment of dysmagnesemia involves correcting the underlying causes if possible and normalizing Mg 2+ . For severe symptomatic hypomagnesemia, parenteral magnesium administration is indicated. Oral administration of Mg 2+ in daily divided doses, however, is the only effective method for total body Mg 2+ repletion. In patients with adequate renal function, hypermagnesemia would mostly self-correct with urine Mg 2+ excretion. If necessary, loop diuretics can be used to enhance renal Mg 2+ excretion. In patients with advanced renal failure and symptomatic hypermagnesemia, intravenous calcium should be considered to stabilize myocardium. Dialysis is the most effective and definitive treatment of hypermagnesemia in patients with renal failure.
Conclusion
We summarize acid-base and electrolyte regulations with updated knowledge. Recent advances on key pathological, clinical and diagnostic features, as well as treatment modalities of several important and common disor-
